Drug Class Unexpectedly Effective on Breast Cancers

Share this article:
Drug Class Unexpectedly Effective on Breast Cancers
Drug Class Unexpectedly Effective on Breast Cancers

(HealthDay News) -- Drugs that normally target cancer cells defective in DNA homologous recombination repair, poly(ADP-Ribose) polymerase (PARP) inhibitors, are also effective on breast cancer cells positive for human epidermal growth factor receptor 2 (HER2), even in the absence of the repair defect, according to a study published in the Sept. 15 issue of Cancer Research.

Noting that PARP inhibitors are known to be effective on cells defective in homologous recombination repair (e.g., showing promise in clinical trials in BRCA-associated breast and ovarian cancers), Somaira Nowsheen, from the University of Alabama at Birmingham School of Medicine, and colleagues examined the effectiveness of PARP inhibitors on breast cancer cells negative or positive for HER2.

The researchers found that HER2-positive breast cancers were sensitive to PARP inhibitors, even those without a defect in homologous repair. HER2-negative breast cancers could be rendered sensitive to PARP inhibitors in vivo and in vitro by overexpressing HER2, with HER2 reduction abrogating this response. Further experiments showed that the ability of HER2 to inhibit the nuclear factor kappa B signaling pathway was associated with sensitivity to PARP inhibitors.

"Our findings indicate that PARP inhibitors may be a novel therapeutic strategy for sporadic HER2-positive breast cancer patients," Nowsheen and colleagues conclude.

Abstract

Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

CTA Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Breast Cancer

Genetic Mutation in Women with African Ancestry Linked to Breast Cancer Mortality

Genetic Mutation in Women with African Ancestry Linked ...

Researchers found 30 genetic mutations in microRNAs, regulatory molecules that influence the development and severity of cancer.

RBM4 Protein Found to be Decreased in Breast and Lung Cancers

RBM4 Protein Found to be Decreased in Breast ...

Researchers have found that RNA-binding protein 4 is extremely decreased in various forms of human cancer, including lung cancers.

Rates of Breast, Ovarian Cancer High Among Jewish Women without Family History

Rates of Breast, Ovarian Cancer High Among Jewish ...

Women of Ashkenazi Jewish descent who tested positive for breast cancer have high rates despite no family history.